Vaccines are now available that help protect against all three serogroups (B, C, and Y) of meningococcal disease that are commonly seen in the United States:
- Meningococcal conjugate vaccines (Menactra®, Menveo®, and MenHibrix®)
- Meningococcal polysaccharide vaccine (Menomune®)
- Serogroup B meningococcal vaccines (Bexsero® and Trumenba®)
For more information on meningococcal vaccines and who should receive them, visit the Meningococcal Vaccine site or Recommendations of the Advisory Committee on Immunization Practices.
- Meningococcal Vaccine Basics
Offers comprehensive information about meningococcal vaccines and other educational tools.
- Who Should Get Vaccinated
- Who Should Not Get Vaccinated
- Possible Reactions to Vaccination
- Vaccine Safety
Q&A on Meningococcal Vaccine Recommendations
In addition to meningococcal conjugate vaccination, clinicians may choose to administer a serogroup B meningococcal vaccine to patients 16 through 23 years old. See answers to common questions about these vaccine recommendations.
Meningococcal Vaccine Resources for Healthcare Professionals
- Meningococcal Vaccination
- Meningococcal Vaccination for Adolescents: Questions and Answers
- Interim Guidance for Control of Serogroup B Meningococcal Disease Outbreaks in Organizational Settings [6 pages]
- Provider Education
- Page last reviewed: June 11, 2015
- Page last updated: November 25, 2015
- Content source:
- Content source: National Center for Immunization and Respiratory Diseases